Cytokinetics Presents Results From COURAGE-ALS at the 34th International Symposium on ALS/MND
As Previously Announced, Reldesemtiv Had No Effect on the Primary Endpoint of Change from Baseline in ALSFRS-R or Key Secondary Endpoints
Trial Discontinued in March 2023 Due to Futility Following Second Planned Interim Analysis
Related news for (CYTK)
- Midday Movers: Biotech Breakouts, Special Payouts, and Strategic Power Plays
- Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Cytokinetics to Participate in the Jefferies Global Healthcare Conference
- Cytokinetics Presents Additional Data Related to Aficamten at the European Society of Cardiology Heart Failure 2025 Congress
- Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)